Complete a 7-day course
ApprovedSmall molecule
Complete a 7-day course is one of 35 small molecule programs targeting Respiratory tract infection. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
80 competitors in Respiratory Tract Infection
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Merrem
BB. Braun Medical Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Tamiflu
CConrado Roberto Hoffmann Filho
Phase 3
Veklury
GileadPhase 2
Quietus
Merck & Co.Phase 2
Rapivab
BBioCryst Pharmaceuticals
Phase 3
Broncho-Vaxom
OOM Pharma SA
Phase 3
Pelubiprofen
Daewon Pharmaceutical Co., Ltd.Phase 3
Singulair
OOrganon and Co
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Respiratory tract infection1 trial
Tailoring Antibiotic Duration for Respiratory Tract Infections in Primary Care
Not yet recruiting·FFundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina·Phase 4·NCT06581367·474 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Complete a 7-day course. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details